...
首页> 外文期刊>Clinical and experimental rheumatology >Intra-articular injection of non-animal stabilised hyaluronic acid (NASHA) for osteoarthritis of the hip: a pilot study.
【24h】

Intra-articular injection of non-animal stabilised hyaluronic acid (NASHA) for osteoarthritis of the hip: a pilot study.

机译:关节腔内注射非动物稳定型透明质酸(NASHA)治疗髋部骨关节炎:一项先导研究。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: This study was undertaken to assess the safety and potential efficacy of intra-articular non-animal stabilised hyaluronic acid (NASHA) in patients with hip OA. METHODS: This was a prospective, open-label, 3-month pilot study of a single intra-articular injection of NASHA in 31 patients. Safety outcomes were measured at 2 weeks and 3 months after treatment, as were efficacy measurements including WOMAC pain, stiffness and physical function scores, and the patient assessment of global disease status. Patients demonstrating reduced pain at month 3 participated in an extension phase (assessment at 6-11 months, 18 patients). Positive response was defined as a > or = 40% reduction in the WOMAC pain score from baseline, together with an absolute decrease of > or = 5 points. RESULTS: Intra-articular injection of NASHA into the hip was well tolerated. The only treatment-related AE was exacerbation of pain and/or stiffness in the treated hip (reported by 9 patients) and there were no serious AEs. Theresponse rate to treatment was 50% at 2 weeks and 54% at 3 months. In the extension population, response rates of 69% and 44% were observed at month 3 and the extension visit, respectively. Global disease status was improved at month 3 compared with baseline in 68% of the patients. CONCLUSIONS: Our results show that a single intra-articular injection of NASHA is a well tolerated and potentially effective therapy in the treatment of hip OA. Further studies of NASHA in this setting are warranted.
机译:目的:本研究旨在评估髋关节骨关节炎患者的关节内非动物稳定透明质酸(NASHA)的安全性和潜在疗效。方法:这是一项前瞻性,开放标签,为期3个月的前期研究,研究对象是31位患者的NASHA关节腔内单次注射。在治疗后2周和3个月测量安全性结果,包括WOMAC疼痛,僵硬和身体功能评分以及整体疾病状态的患者评估在内的功效测量也进行了测量。在第3个月疼痛减轻的患者参加了延长阶段(6-11个月的评估,18例患者)。阳性反应定义为WOMAC疼痛评分从基线降低>或= 40%,同时绝对降低>或= 5分。结果:髋关节内关节腔注射NASHA耐受性良好。唯一与治疗有关的AE是受治疗的髋关节疼痛和/或僵硬加重(有9位患者报告),并且没有严重的AE。 2周时对治疗的反应率为50%,3个月时为54%。在推广人群中,在第3个月和推广访问中分别观察到69%和44%的响应率。与基线相比,在68%的患者中,第3个月的总体疾病状况有所改善。结论:我们的结果表明,单次NASHA关节腔内注射是治疗髋骨关节炎的一种耐受良好且潜在有效的疗法。在这种情况下,有必要进一步研究NASHA。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号